Reported results
- Total revenue for the three months ended September 30, 2026 was $47,628.
- Selling, general and administrative expenses were $2,640,388 for the three months ended September 30, 2026.
- Research and development expenses were $318,906 for the three months ended September 30, 2026.
- Total contra-R&D expenses for the three months ended September 30, 2026 were approximately $4.7 million.
- Cash and cash equivalents were $11,531,684 as of September 30, 2026.
Guidance
- The Company does not expect the amount of product revenue from Flora Sync LF5 and DARE to PLAY Sildenafil Cream to be material during 2026.
- Revenue from DARE to RECLAIM estradiol and progesterone intravaginal ring is targeted to begin in 2027.
Notes
The Company recognizes amounts received under grant and governmental funding awards as contra-R&D expenses.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
